RIP Onglyza? And condolences to those who continue to lose loved ones to bad medicine

 deadly prescription      willy wonka

 Diabetes drug ONGLYZA increases death risk: FDA

Here’s another diabetes drug, ONGLYZA, that will need to be “readdressed” by the FDA as it has proven to be associated with an increased death rate.  It’s just another drug for type 2 diabetes that was very quickly studied, obtained  FDA approval, distributed this drug via prescription to millions of peopole….and has been subsequently linked to diseases like pancreatic cancer, bladder cancer, liver cancer, kidney cancer….after millions of prescriptions have been written.  In this case, the FDA doesn’t even know why it’s killing people..  Imagine that.

Please realize that the pharmaceutical industry nets billions of dollars a year.  What’s it to them if a  drug is found to be harmful or deadly?  They repay a paltry amount to victims  or victim’s families of those  injured or killed by the medicine.  And then, after the checks are written, the very same pharmaceutical company continues on  as if nothing happened, having still made a hefty profit (even after they pay victims) from the dangerous or deadly prescription drug.

Big Pharma and the FDA are obviously hooked up.  Big Pharma makes a new medication, gives money to get it on the market (to the FDA).  When it fails, the FDA might blacklist it or force the company to make some changes.  The pharmaceutical company and the FDA both makes tons of money….and we are left with drug induced medical conditions or death.  Money…the root of all evil….

(Reuters) – AstraZeneca Plc’s diabetes drug Onglyza appears to be associated with an increased rate of death, according to a review of data published by the U.S. Food and Drug Administration on Friday.

While the primary clinical trial results did not show a statistically significant increase in the rate of death, a more detailed analysis examining only patients who took Onglyza suggests “a significantly increased risk of all-cause mortality,” FDA staff said in their review.

 

FiercePharma earlier in the week;

FDA experts will grill a couple of diabetes meds next Tuesday, and the outcome of that debate could put a damper on sales. The drugs: AstraZeneca’s ($AZN) Onglyza and Takeda‘s Nesina, both DPP-4 blood sugar-fighters. The questions: Do they really increase the risk of heart failure? And if so, what’s to be done about it?

There’s a broader question, too. If these meds ratchet up the risk of heart failure, what does that say about the DPP-4 meds as a group, which includes Merck & Co.’s ($MRK) blockbuster Januvia franchise.

The FDA is convening an advisory committee to consider data from the SAVOR outcomes trial, which suggested that Onglyza patients were more likely to be hospitalized with heart failure. In the 16,000-patient study, 27% more Onglyza patients ended up in the hospital with heart failure, compared with patients in the control arm.

(Reuters) – AstraZeneca Plc’s diabetes drug Onglyza appears to be associated with an increased rate of death, according to a review of data published by the U.S. Food and Drug Administration on Friday.

While the primary clinical trial results did not show a statistically significant increase in the rate of death, a more detailed analysis examining only patients who took Onglyza suggests “a significantly increased risk of all-cause mortality,” FDA staff said in their review.

FiercePharma earlier in the week;

FDA experts will grill a couple of diabetes meds next Tuesday, and the outcome of that debate could put a damper on sales. The drugs: AstraZeneca’s ($AZN) Onglyza and Takeda‘s Nesina, both DPP-4 blood sugar-fighters. The questions: Do they really increase the risk of heart failure? And if so, what’s to be done about it?

There’s a broader question, too. If these meds ratchet up the risk of heart failure, what does that say about the DPP-4 meds as a group, which includes Merck & Co.’s ($MRK) blockbuster Januvia franchise.

The FDA is convening an advisory committee to consider data from the SAVOR outcomes trial, which suggested that Onglyza patients were more likely to be hospitalized with heart failure. In the 16,000-patient study, 27% more Onglyza patients ended up in the hospital with heart failure, compared with patients in the control arm.

 

 

Advertisements

About Diane Kress

Author of The New York Times Bestseller; The Metabolism Miracle, The Metabolism Miracle Cookbook, and The Diabetes Miracle. and The Metabolism Miracle, Revised Edition. Owner, developer, and administrator of The Metabolism Miracle's support site: www.Miracle-Ville.com. Registered Dietitian, Certified Diabetes Educator, www.themetabolismmiracle.com www.thediabetesmiracle.com www.miracle-ville.com Email: dietquestions@ymail.com
This entry was posted in ADA, AMA, AND, Diane Kress, insulin resistance, LADA, low carb, low carbohydrate, Met B, Metabolic syndrome, Metabolism B, Miracle-Ville.com, monitoring blood glucose, obesity, Onglyza, overweight, PCOS, pre diabetes, prediabetes, The Diabetes Miracle, The Metabolism Miracle, The Metabolism Miracle Cookbook, The Metabolism Miracle Update, type 1.5 diabetes, type 2 diabetes, Uncategorized, weigh in and tagged , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s